We are a diverse team with deep knowledge of the healthcare and neurology space and expertise in biomedical research, clinical practice and business/finance.

J. KENT WERNER, MD, PHD

Chief Executive Officer, Founder

Kent Werner is a board-certified neurologist and neuroscientist.  He holds Assistant Professor appointments in the Departments of Neurology at the Uniformed Services University and adjunct at Johns Hopkins University. He has 14 years of experience in biomedical research and seven years in clinical training. Kent received his MD and PhD in Cellular and Molecular Medicine in the department of Neuroscience in 2012 at the Johns Hopkins University under Dr. Solomon Snyder. His areas of research include  neurodegenerative conditions to include dementia and traumatic brain injury and their relationship to sleep.

 

CHRISTOPHER "KITT" BURCH, MBA

Chief Operating Officer, Founder

Christopher served in the US Army Special Forces (Green Berets) for over seven years, where he built high-performance teams in chaotic and fluid environments. He holds an MBA from Johns Hopkins Carey Business School, where he specialized in strategic marketing and risk management, and has studied data science at the Johns Hopkins School of Public Health.

 

SEAN L. EVANS, PHD

Consultant, Founder

Sean has over 10 years of experience in life science research. In addition to leading business development efforts for Cogentis, he also works as an Associate Director of Business Development with Johns Hopkins Technology Ventures where he helps to identify and foster strategic partnerships with life science companies to accelerate academic innovation. Sean received an MS in Biotechnology (2008) and PhD in Microbiology and Immunology (2014) from the Johns Hopkins University.

 

Yvonne Angell, PHD

Vice President of Discovery

Yvonne has over 16 years of experience in the pharmaceutical industry. She has led research teams at Eli Lilly, Wyeth, Affymax, Ipsen Bioscience and is currently working on consulting projects through her own consulting firm, Picotide Technologies. Her primary expertise is in design, synthesis and lead optimization of novel peptides, peptidomimetics and peptide conjugates. Yvonne received her PhD in Medicinal Chemistry at the University of Wisconsin-Madison and post-doctoral work at the University of Minnesota.